{"drugs":["Avosil","Compound W","Duofilm","Mediplast","Occlusal-HP","Sal-Plant Gel","Salicylic Acid","Stri-Dex","Trans-Ver-Sal"],"mono":{"0":{"id":"529100-s-0","title":"Generic Names","mono":"Salicylic Acid"},"1":{"id":"529100-s-1","title":"Dosing and Indications","sub":{"0":{"id":"529100-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acne vulgaris:<\/b> apply TOPICALLY in concentrations of 0.5% to 10%<\/li><li><b>Disorder of skin, Hyperkeratotic:<\/b> gel, apply TOPICALLY to the affected area and occlude the area at night<\/li><li><b>Disorder of skin, Hyperkeratotic:<\/b> shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears<\/li><li><b>Psoriasis:<\/b> apply TOPICALLY in concentrations of 3% to 6%<\/li><li><b>Removal of wart:<\/b> apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks<\/li><\/ul>"},"1":{"id":"529100-s-1-5","title":"Pediatric Dosing","mono":"<b>Psoriasis:<\/b> apply TOPICALLY in concentrations up to 6% "},"3":{"id":"529100-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne vulgaris<\/li><li>Disorder of skin, Hyperkeratotic<\/li><li>Psoriasis<\/li><li>Removal of wart<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Onychomycosis due to dermatophyte<br\/>"}}},"3":{"id":"529100-s-3","title":"Contraindications\/Warnings","sub":{"1":{"id":"529100-s-3-10","title":"Precautions","mono":"<ul><li>Dermatologic:<\/li><li>-- may cause irritation or dryness, especially when used concomitantly with other topical acne medication; if excessive irritation occurs, decrease dose or discontinue use<\/li><li>Immunologic:<\/li><li>-- rare, serious, and potentially life-threatening allergic reactions or severe irritation have been reported with over-the-counter topical acne products; test dose recommended; discontinue and seek emergency medical attention if serious hypersensitivity reaction occurs<\/li><li>Concomitant use:<\/li><li>-- increased risk for skin irritation and dryness with other topical acne medication; if irritation occurs, use one topical acne medication at a time as directed by physician<\/li><li>Other:<\/li><li>-- keep out of reach of children; if swallowed, seek medical help or call Poison Control Center immediately<\/li><li>-- avoid contact with eyes<\/li><li>-- for external use only<\/li><\/ul>"},"2":{"id":"529100-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},"3":{"id":"529100-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}}},"4":{"id":"529100-s-4","title":"Drug Interactions","sub":[{"id":"529100-s-4-13","title":"Contraindicated","mono":"<ul>Ketorolac (theoretical)<\/ul>"},{"id":"529100-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Desirudin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Femoxetine (probable)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nefazodone (probable)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Varicella Virus Vaccine (probable)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"529100-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Acenocoumarol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Anisindione (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dicumarol (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Phenindione (probable)<\/li><li>Phenprocoumon (probable)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Talinolol (probable)<\/li><li>Tamarind (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Warfarin (probable)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},"5":{"id":"529100-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Burning sensation, Erythema, Pruritus, Stinging of skin<br\/><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Salicylate toxicity<\/li><\/ul>"},"6":{"id":"529100-s-6","title":"Drug Name Info","sub":{"0":{"id":"529100-s-6-17","title":"US Trade Names","mono":"<ul><li>Compound W<\/li><li>Duofilm<\/li><li>Mediplast<\/li><li>Occlusal-HP<\/li><li>Sal-Plant Gel<\/li><li>Trans-Ver-Sal<\/li><li>Stri-Dex<\/li><li>Avosil<\/li><\/ul>"},"2":{"id":"529100-s-6-19","title":"Class","mono":"<ul><li>Analgesic<\/li><li>Antiacne<\/li><li>Antiacne Keratolytic<\/li><li>Antipsoriatic<\/li><li>Keratolytic<\/li><li>NSAID<\/li><li>Salicylate, Non-Aspirin<\/li><\/ul>"},"3":{"id":"529100-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"529100-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"529100-s-7","title":"Mechanism Of Action","mono":"Topical: Salicylic acid facilitates desquamation by solubilizing the intercellular cement that binds scales in the stratum corneum, thereby loosening the keratin. This keratolytic effect may provide an antifungal action because removal of the stratum corneum suppresses fungal growth; it also aids in the penetration of other antifungal agents. Salicylic acid also has a mild antiseptic action.<br\/>"},"9":{"id":"529100-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>(Salex(TM), Keralyt(R) Gel) topical use only; not for ophthalmic, oral, or intravaginal use<br\/><\/li><li><b>Topical<\/b><br\/><ul><li>(Salex(TM), Keralyt(R) Gel) hydrate skin for 5 min prior to application; apply cream, lotion, gel to affected area and occlude the area at night<\/li><li>(Salex(TM), Keralyt(R) Gel) wash off medication in the morning<\/li><\/ul><\/li><\/ul>"},"10":{"id":"529100-s-10","title":"Monitoring","mono":"<ul><li>improvement of acne, psoriasis, or other skin disorder<\/li><li>signs and symptoms of salicylate toxicity; in patients with prolonged use over large areas<\/li><\/ul>"},"11":{"id":"529100-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Topical Cream: 6 %<\/li><li>Topical Foam: 6 %<\/li><li>Topical Liquid: 3 %, 5 %<\/li><li>Topical Lotion: 6 %<\/li><li>Topical Shampoo: 6 %<\/li><li>Topical Solution: 17 %, 26 %, 27.5 %<\/li><\/ul><\/li><li><b>Aveeno Clear Complexion Cream Cleanser<\/b><br\/>Topical Soap: 2 %<br\/><\/li><li><b>Aveeno Clear Complexion Daily Cleansing Pads<\/b><br\/>Topical Pad: 0.5 %<br\/><\/li><li><b>Aveeno Clear Complexion Daily Moisturizer<\/b><br\/>Topical Lotion: 0.5 %<br\/><\/li><li><b>Aveeno Clear Complexion Foaming Cleanser<\/b><br\/>Topical Foam: 0.5 %<br\/><\/li><li><b>Bensal HP<\/b><br\/>Topical Ointment: 3 %<br\/><\/li><li><b>Clean&amp;Clear Advantage Acne Control 3in1FoamingWash<\/b><br\/>Topical Soap: 2 %<br\/><\/li><li><b>Clean &amp; Clear Advantage Acne Moisturizer<\/b><br\/>Topical Lotion: 0.5 %<br\/><\/li><li><b>Clean &amp; Clear Advantage Acne Spot Treatment<\/b><br\/>Topical Gel\/Jelly: 2 %<br\/><\/li><li><b>Clean &amp; Clear Advantage Daily Soothing Acne Scrub<\/b><br\/>Topical Soap: 2 %<br\/><\/li><li><b>Clean &amp; Clear Advantage Daily Soothing Acne Wash<\/b><br\/>Topical Soap: 2 %<br\/><\/li><li><b>Clean &amp; Clear Advantage Mark Treatment<\/b><br\/>Topical Lotion: 2 %<br\/><\/li><li><b>Clean &amp; Clear Advantage Oil Absorbing Cleanser<\/b><br\/>Topical Cream: 0.5 %<br\/><\/li><li><b>Clean &amp; Clear Blackhead Eraser Cleansing Mask<\/b><br\/>Topical Soap: 0.5 %<br\/><\/li><li><b>Clean &amp; Clear Blackhead Eraser Scrub<\/b><br\/>Topical Soap: 2 %<br\/><\/li><li><b>Clean &amp; Clear Deep Cleaning Astringent<\/b><br\/>Topical Solution: 0.5 %, 2 %<br\/><\/li><li><b>Clean &amp; Clear Dual Action Moisturizer<\/b><br\/>Topical Lotion: 0.5 %<br\/><\/li><li><b>Clean and Clear Advantage Popped Pimple Relief<\/b><br\/>Topical Paste: 0.5 %<br\/><\/li><li><b>Compound W One Step Wart Remover<\/b><br\/>Topical Pad: 40 %<br\/><\/li><li><b>Compound W<\/b><br\/><ul><li>Topical Gel\/Jelly: 17 %<\/li><li>Topical Liquid: 17 %<\/li><\/ul><\/li><li><b>DHS Sal<\/b><br\/>Topical Liquid: 3 %<br\/><\/li><li><b>Doctor's Choice Advanced Wound Care Corn &amp; Callus Remover<\/b><br\/>Topical Pad: 40 %<br\/><\/li><li><b>Drytex<\/b><br\/>Topical Liquid: 2 %<br\/><\/li><li><b>DuoFilm<\/b><br\/><ul><li>Topical Liquid: 17 %<\/li><li>Topical Solution: 17 %<\/li><\/ul><\/li><li><b>Durasal<\/b><br\/>Topical Solution: 26 %<br\/><\/li><li><b>Freezone Maximum Strength<\/b><br\/>Topical Liquid: 17.6 %<br\/><\/li><li><b>Fung-O<\/b><br\/>Topical Liquid: 17 %<br\/><\/li><li><b>Gets-It Corn\/Callus Remover<\/b><br\/>Topical Liquid: 12 %<br\/><\/li><li><b>Gordofilm<\/b><br\/>Topical Liquid: 16.7 %<br\/><\/li><li><b>Keralyt Gel<\/b><br\/>Topical Gel\/Jelly: 6 %<br\/><\/li><li><b>Keralyt<\/b><br\/>Topical Gel\/Jelly: 3 %<br\/><\/li><li><b>Leader Corn and Callus Remover<\/b><br\/>Topical Solution: 12.6 %<br\/><\/li><li><b>Leader Wart Remover<\/b><br\/>Topical Solution: 17 %<br\/><\/li><li><b>Lupicare Dandruff<\/b><br\/>Topical Cream: 2.5 %<br\/><\/li><li><b>Lupicare II Psoriasis Skin<\/b><br\/>Topical Cream: 2.5 %<br\/><\/li><li><b>Lupicare Psoriasis Scalp<\/b><br\/>Topical Cream: 2.5 %<br\/><\/li><li><b>Lupicare Psoriasis<\/b><br\/>Topical Liquid: 2 %<br\/><\/li><li><b>Mediplast<\/b><br\/>Topical Pad: 40 %<br\/><\/li><li><b>Mosco Corn &amp; Callus Remover<\/b><br\/>Topical Liquid: 17.6 %<br\/><\/li><li><b>Neutrogena Acne Wash<\/b><br\/>Topical Liquid: 2 %<br\/><\/li><li><b>Neutrogena T\/Sal Maximum Strength<\/b><br\/>Topical Liquid: 3 %<br\/><\/li><li><b>P &amp; S Shampoo<\/b><br\/>Topical Shampoo: 2 %<br\/><\/li><li><b>Palmer's Skin Success Acne Cleanser<\/b><br\/>Topical Liquid: 0.5 %<br\/><\/li><li><b>PanOxyl Exfoliating<\/b><br\/>Topical Solution: 0.5 %<br\/><\/li><li><b>Rite Aid Acne Cleanser<\/b><br\/>Topical Solution: 2 %<br\/><\/li><li><b>Rite Aid AcnePads<\/b><br\/>Topical Pad: 2 %<br\/><\/li><li><b>Rite Aid Apricot Scrub<\/b><br\/>Topical Soap: 2 %<br\/><\/li><li><b>Rite Aid Foot Care Corn Removers<\/b><br\/>Topical Pad: 40 %<br\/><\/li><li><b>Rite Aid Liquid Wart Remover<\/b><br\/>Topical Solution: 17 %<br\/><\/li><li><b>Rite Aid Medicated One-Step Corn Remover<\/b><br\/>Topical Pad: 40 %<br\/><\/li><li><b>Rite Aid Scalp Itch &amp; Dandruff Relief<\/b><br\/>Topical Liquid: 3 %<br\/><\/li><li><b>Rite Aid Wart Remover Gel<\/b><br\/>Topical Gel\/Jelly: 17 %<br\/><\/li><li><b>Salactic Film<\/b><br\/>Topical Liquid: 17 %<br\/><\/li><li><b>Salacyn<\/b><br\/><ul><li>Topical Cream: 6 %<\/li><li>Topical Lotion: 6 %<\/li><\/ul><\/li><li><b>Salex<\/b><br\/><ul><li>Topical Lotion: 6 %<\/li><li>Topical Shampoo: 6 %<\/li><\/ul><\/li><li><b>Salkera<\/b><br\/>Topical Foam: 6 %<br\/><\/li><li><b>Sal-Plant Gel<\/b><br\/>Topical Gel\/Jelly: 17 %<br\/><\/li><li><b>Salvax<\/b><br\/>Topical Foam: 6 %<br\/><\/li><li><b>Scalpicin<\/b><br\/>Topical Solution: 3 %<br\/><\/li><li><b>UltraSal-ER<\/b><br\/>Topical Solution: 28.5 %<br\/><\/li><li><b>Virasal<\/b><br\/>Topical Solution: 27.5 %<br\/><\/li><li><b>Zapzyt Face &amp; Body Wash<\/b><br\/>Topical Gel\/Jelly: 2 %<br\/><\/li><li><b>Zapzyt Pore Clearing Scrub<\/b><br\/>Topical Soap: 2 %<br\/><\/li><\/ul>"},"12":{"id":"529100-s-12","title":"Toxicology","sub":[{"id":"529100-s-12-31","title":"Clinical Effects","mono":"<b>SALICYLATES<\/b><br\/>USES: Salicylates are used primarily as an analgesic, antipyretic, anti-inflammatory, and antiplatelet agent. Found in many over-the-counter preparations in oral and topical forms. It may also be found in combination with other agents such as narcotics, barbiturates, and caffeine. Topical forms are often used as rubefacients. Also found in some essential oils in high concentrations such as oil of wintergreen. PHARMACOLOGY: Salicylates inhibit cyclooxygenase, thereby reducing the formation of prostaglandins, and cause platelet dysfunction. TOXICOLOGY: Salicylates stimulate the respiratory center in the brainstem, interfere with the Krebs cycle (limiting ATP production), uncouple oxidative phosphorylation (causing accumulation of pyruvic and lactic acid and heat production), and increase fatty acid metabolism (generating ketone bodies). The net result is a mixed respiratory alkalosis and metabolic acidosis. EPIDEMIOLOGY: Common poisoning which can result in significant morbidity and mortality. MILD TO MODERATE TOXICITY: GI upset, tinnitus, tachypnea, and respiratory alkalosis. SEVERE TOXICITY: Metabolic acidosis, hyperpnea, diaphoresis, fever, altered mental status, seizures, coma, cerebral edema, pulmonary edema and death. Chronic overdoses present more insidiously and may be subtle, especially in the elderly, and may consist primarily of neurologic manifestations such as confusion, delirium, and agitation. Coagulopathy, hepatic injury, and dysrhythmias are rare complications of severe overdose. ADVERSE EFFECTS: GI upset and tinnitus. <br\/>"},{"id":"529100-s-12-32","title":"Treatment","mono":"<b>SALICYLATES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: An initial salicylate level should be obtained and repeated every 1 to 2 hours until a clear peak and decline is observed. Start intravenous fluids. Concentrations greater than 30 mg\/dL and rising should be treated with urine alkalinization. The presence of a large anion gap metabolic acidosis or altered mental status indicates a more severe poisoning. MANAGEMENT OF SEVERE TOXICITY: Patients with severe poisoning should be continued on urine alkalinization; hemodialysis should be strongly considered. Relative indications for hemodialysis include: renal failure, congestive heart failure, altered mental status, seizures, evidence of cerebral edema, worsening acidosis despite adequate resuscitation, persistently rising salicylate concentrations despite adequate treatment (greater than 50 to 60 mg\/dL in a chronic poisoning or levels greater than 90 to 100 mg\/dL in an acute overdose). Patients with an altered mental status may have cerebral edema; a head CT should be obtained. Mannitol can be given for cerebral edema. Severely ill patients may require respiratory support and intubation. Maintain preintubation minute ventilation at the same high respiratory rate because once the patient's respiratory drive is removed metabolic acidosis may worsen.<\/li><li>Decontamination: PREHOSPITAL: Prehospital decontamination with activated charcoal can be considered for large ingestions in patients with normal mental status in whom there will be a delay to definitive healthcare, but a poison center should be consulted first. HOSPITAL: Activated charcoal should be administered to any patient who presents within 2 hours of a significant ingestion, can adequately protect their airway, and has no alteration in mental status. Administer activated charcoal to patients with large ingestions who present after 2 hours, as salicylate absorption can be delayed and erratic. Consider the use of gastric lavage for patients that present with large ingestions within 2 hours.<\/li><li>Airway management: Patients who are comatose or with altered mental status may need mechanical respiratory support and orotracheal intubation. If the patient requires intubation, monitor end tidal CO2 and arterial blood gases frequently and maintain the preintubation minute ventilation to prevent severe acidosis.<\/li><li>Antidote: There is no specific antidote.<\/li><li>Monitoring of patient: Obtain serial salicylate levels every 1 to 2 hours until concentrations have peaked and are declining; basic metabolic panel every 2 hours until clinical improvement; arterial or venous blood gas for patients undergoing urinary alkalinization or moderate\/severe toxicity. In addition, obtain CBC, liver enzymes, renal function studies, INR and PTT in patients with clinical evidence of moderate\/severe toxicity.<\/li><li>Fluid\/electrolyte balance regulation: Correct dehydration with 0.9% saline 10 to 20 mL\/kg\/hour over 1 to 2 hours until a good urine flow is obtained (at least 3 to 6 mL\/kg\/hour).  In patients in whom urinary alkalinization is being considered, initial hydration may be with 10 to 20 mL\/kg of D5W with 88 to 132 mEq of bicarbonate added.  Patients in shock may require more rapid fluid administration. Correct hypokalemia with intravenous potassium boluses and oral potassium. Monitor urine output and pH hourly.<\/li><li>Acidosis: Administer 1 to 2 mEq\/kg NaHCO3 by IV bolus and begin urinary alkalinization.  Monitor blood gases and urinary pH to guide frequency and quantity of administration. Patients with refractory acidosis, inability to maintain appropriate respiratory alkalosis, or acidemia should be treated with hemodialysis.<\/li><li>Alkaline diuresis: Urinary alkalization will increase elimination of salicylates. Place 150 mEq (3 ampules) of NaHCO3 in 1 liter of 5% dextrose to provide an isotonic solution; administer 10 to 20 mL\/kg initially as a bolus, then infuse at 2 to 3 mL\/kg\/hour. Administer 20 to 40 mEq\/L of potassium chloride as an IV infusion as needed to maintain normokalemia. Oral potassium may be administered if tolerated. Hypokalemia and hypocalcemia may occur with alkalinization and hypokalemia can prevent the development of an alkaline urine. Monitor serum electrolytes (in particular potassium and calcium), serum and urinary pH frequently (every 1 to 2 hours); goal of therapy is a urine pH of 7.5 to 8.<\/li><li>Hemodialysis: Hemodialysis efficiently removes salicylate and corrects acid base and electrolyte abnormalities. Hemodialysis is recommended in patients with high serum salicylate levels (greater than 90 to 100 mg\/dL after acute overdose, to 50 to 60 mg\/dL with chronic intoxication), refractory acidosis, inability to maintain appropriate respiratory alkalosis, acidemia, evidence of CNS toxicity (i.e., seizures, mental status depression, persistent confusion, coma, and cerebral edema), progressive clinical deterioration despite appropriate fluid therapy and attempted urinary alkalinization, acute lung injury, inability to tolerate sodium bicarbonate (e.g., renal insufficiency, pulmonary edema), refractory\/profound electrolyte disturbances, or renal failure. The clinical condition of the patient is more important than the serum salicylate concentration in determining the need for hemodialysis, especially in patients with chronic toxicity or delayed presentation after acute overdose. In patients with early presentation after acute overdose, serum concentrations approaching 100 mg\/dL warrant consideration for dialysis even with mild or moderate clinical manifestations of toxicity. Administer a second dose of activated charcoal to patients with persistently rising salicylate levels despite urinary alkalinization and an initial dose of activated charcoal. Consider whole bowel irrigation with polyethylene glycol for patients with large ingestions of enteric coated products if they are alert and able to protect the airway.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions of less than 150 mg\/kg or 6.5 g, whichever is less, of aspirin equivalent doses can generally be observed at home with normal follow-up procedures. Consider follow-up at periodic intervals of approximately 12 hours after acute ingestion of non-enteric coated salicylate products or 24-hours for enteric-coated aspirin. ADMISSION CRITERIA: Patients who have a rising salicylate concentration, metabolic acidosis, or alterations in mental status should be admitted to an intensive care setting. OBSERVATION CRITERIA: Patients with intentional ingestions and those with unintentional ingestions greater than 150 mg\/kg or 6.5 g of aspirin equivalent doses, whichever is less, should be evaluated in a healthcare facility. For oil of wintergreen (98% methylsalicylate), greater than a lick or taste by children under 6 years of age or greater than 4 mL by patients 6 years of age and older requires referral to an emergency department for evaluation. Patients who have a well defined peak and decline in salicylate concentration and mild to moderate symptoms that resolve with treatment can often be treated and released from an ED observation unit. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings and for recommendations on determining the need for hemodialysis. Women in the third trimester of pregnancy who do not require referral to a healthcare facility for other reasons (ie ingested dose or symptoms) should be referred to an obstetrician for outpatient follow up and assessment of maternal fetal risk.<\/li><\/ul>"},{"id":"529100-s-12-33","title":"Range of Toxicity","mono":"<b>SALICYLATES <\/b><br\/>TOXICITY: ACUTE INGESTION: The acute ingestion of less than 150 mg\/kg or 6.5 g of aspirin equivalent, whichever is less, is not expected to cause significant toxicity. For oil of wintergreen (98% methylsalicylate), greater than a lick or taste by children under 6 years of age or greater than 4 mL by patients 6 years of age and older may cause toxicity and requires referral to an emergency department for evaluation. FATALITIES: As little as 5 mL of oil of wintergreen has resulted in pediatric deaths. THERAPEUTIC DOSE: For children an analgesic or antipyretic dose is 10 to 15 mg\/kg; 325 to 650 mg for adults.<br\/>"}]},"13":{"id":"529100-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to use a test dose for over-the-counter (OTC) products due to potential hypersensitivity reactions. Apply small amount to skin for 3 days and if no discomfort occurs, use product as directed.<\/li><li>Warn patient that prolonged use over large skin areas may cause salicylate toxicity.<\/li><li>Side effects may include skin erythema, irritation, scaling, or dryness.<\/li><li>Advise patient to avoid contact with eyes and mucous membranes.<\/li><\/ul>"}}}